Serum VEGF Levels in Ovarian Cancer
Author Information
Author(s): A Obermair, C Tempfer, L Hefler, O Preyer, A Kaider, R Zeillinger, S Leodolter, C Kainz
Primary Institution: University Hospital of Vienna
Hypothesis
The study aims to determine the value of preoperative serum VEGF levels in the early diagnosis of ovarian cancer and in the differential diagnosis of adnexal masses.
Conclusion
VEGF does not appear to be a useful tool in the early diagnosis of ovarian cancer or for indicating the absence or presence of malignancy in patients with an adnexal mass.
Supporting Evidence
- VEGF levels were significantly lower in healthy women compared to those with ovarian cancer.
- At a threshold of 363.7 pg/ml, VEGF had a sensitivity of 54% and specificity of 77%.
- CA 125 was found to be a more reliable marker for predicting malignancy than VEGF.
Takeaway
The study looked at a protein called VEGF in the blood of women to see if it could help find ovarian cancer early, but it turns out it doesn't really help.
Methodology
Preoperative serum VEGF levels were examined in healthy women, patients with benign ovarian cysts, and ovarian cancer patients using an ELISA.
Limitations
The study mainly included advanced-stage ovarian cancer patients, which may affect the generalizability of the results.
Participant Demographics
Mean age of participants was 47 years, with a range from 21 to 79 years.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website